vs
Apellis Pharmaceuticals, Inc.（APLS）与ChargePoint Holdings, Inc.（CHPT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ChargePoint Holdings, Inc.的1.9倍（$199.9M vs $105.7M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -49.7%，领先20.2%），ChargePoint Holdings, Inc.同比增速更快（6.1% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-23.6M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ChargePoint Holdings, Inc.是总部位于美国加利福尼亚州坎贝尔的电动汽车基础设施企业，运营着全球规模最大的独立所有电动汽车充电桩在线网络，站点覆盖14个国家，同时也自主研发生产相关充电技术设备。
APLS vs CHPT — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $105.7M |
| 净利润 | $-59.0M | $-52.5M |
| 毛利率 | — | 30.7% |
| 营业利润率 | -25.6% | -42.0% |
| 净利率 | -29.5% | -49.7% |
| 营收同比 | -5.9% | 6.1% |
| 净利润同比 | -62.2% | 32.4% |
| 每股收益（稀释后） | $-0.40 | $-2.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $105.7M | ||
| Q3 25 | $458.6M | $98.6M | ||
| Q2 25 | $178.5M | $97.6M | ||
| Q1 25 | $166.8M | $101.9M | ||
| Q4 24 | $212.5M | $99.6M | ||
| Q3 24 | $196.8M | $108.5M | ||
| Q2 24 | $199.7M | $107.0M | ||
| Q1 24 | $172.3M | $115.8M |
| Q4 25 | $-59.0M | $-52.5M | ||
| Q3 25 | $215.7M | $-66.2M | ||
| Q2 25 | $-42.2M | $-57.1M | ||
| Q1 25 | $-92.2M | $-58.8M | ||
| Q4 24 | $-36.4M | $-77.6M | ||
| Q3 24 | $-57.4M | $-68.9M | ||
| Q2 24 | $-37.7M | $-71.8M | ||
| Q1 24 | $-66.4M | $-94.7M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 28.7% | ||
| Q1 25 | — | 28.2% | ||
| Q4 24 | — | 22.9% | ||
| Q3 24 | — | 23.6% | ||
| Q2 24 | — | 22.1% | ||
| Q1 24 | — | 19.3% |
| Q4 25 | -25.6% | -42.0% | ||
| Q3 25 | 48.7% | -59.8% | ||
| Q2 25 | -18.6% | -55.1% | ||
| Q1 25 | -50.0% | -53.9% | ||
| Q4 24 | -12.3% | -68.4% | ||
| Q3 24 | -24.0% | -57.8% | ||
| Q2 24 | -14.7% | -62.7% | ||
| Q1 24 | -36.0% | -80.2% |
| Q4 25 | -29.5% | -49.7% | ||
| Q3 25 | 47.0% | -67.1% | ||
| Q2 25 | -23.6% | -58.5% | ||
| Q1 25 | -55.3% | -57.7% | ||
| Q4 24 | -17.1% | -77.9% | ||
| Q3 24 | -29.2% | -63.5% | ||
| Q2 24 | -18.9% | -67.1% | ||
| Q1 24 | -38.5% | -81.8% |
| Q4 25 | $-0.40 | $-2.23 | ||
| Q3 25 | $1.67 | $-2.85 | ||
| Q2 25 | $-0.33 | $-0.12 | ||
| Q1 25 | $-0.74 | $-5.83 | ||
| Q4 24 | $-0.30 | $-3.56 | ||
| Q3 24 | $-0.46 | $-3.22 | ||
| Q2 24 | $-0.30 | $-0.17 | ||
| Q1 24 | $-0.54 | $-23.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $180.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $38.4M |
| 总资产 | $1.1B | $848.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $180.5M | ||
| Q3 25 | $479.2M | $194.1M | ||
| Q2 25 | $370.0M | $195.9M | ||
| Q1 25 | $358.4M | $224.6M | ||
| Q4 24 | $411.3M | $219.4M | ||
| Q3 24 | $396.9M | $243.3M | ||
| Q2 24 | $360.1M | $261.9M | ||
| Q1 24 | $325.9M | $327.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $38.4M | ||
| Q3 25 | $401.2M | $70.7M | ||
| Q2 25 | $156.3M | $118.6M | ||
| Q1 25 | $164.2M | $137.5M | ||
| Q4 24 | $228.5M | $181.0M | ||
| Q3 24 | $237.1M | $230.9M | ||
| Q2 24 | $264.3M | $277.9M | ||
| Q1 24 | $266.7M | $327.7M |
| Q4 25 | $1.1B | $848.0M | ||
| Q3 25 | $1.1B | $870.3M | ||
| Q2 25 | $821.4M | $897.6M | ||
| Q1 25 | $807.3M | $898.2M | ||
| Q4 24 | $885.1M | $966.3M | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.1B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-22.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-23.6M |
| 自由现金流率自由现金流/营收 | -7.1% | -22.3% |
| 资本支出强度资本支出/营收 | 0.1% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-69.6M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $-22.5M | ||
| Q3 25 | $108.5M | $-6.2M | ||
| Q2 25 | $4.4M | $-33.0M | ||
| Q1 25 | $-53.4M | $-2.7M | ||
| Q4 24 | $19.4M | $-30.6M | ||
| Q3 24 | $34.1M | $-51.2M | ||
| Q2 24 | $-8.3M | $-62.5M | ||
| Q1 24 | $-133.0M | $-41.5M |
| Q4 25 | $-14.3M | $-23.6M | ||
| Q3 25 | $108.3M | $-7.5M | ||
| Q2 25 | $4.4M | $-34.0M | ||
| Q1 25 | $-53.4M | $-4.6M | ||
| Q4 24 | $19.3M | $-33.4M | ||
| Q3 24 | — | $-55.0M | ||
| Q2 24 | $-8.4M | $-66.0M | ||
| Q1 24 | $-133.3M | $-46.2M |
| Q4 25 | -7.1% | -22.3% | ||
| Q3 25 | 23.6% | -7.6% | ||
| Q2 25 | 2.5% | -34.9% | ||
| Q1 25 | -32.0% | -4.5% | ||
| Q4 24 | 9.1% | -33.5% | ||
| Q3 24 | — | -50.7% | ||
| Q2 24 | -4.2% | -61.7% | ||
| Q1 24 | -77.3% | -39.9% |
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | 2.8% | ||
| Q3 24 | 0.0% | 3.5% | ||
| Q2 24 | 0.0% | 3.2% | ||
| Q1 24 | 0.2% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CHPT
| Products | $56.4M | 53% |
| License And Service | $42.0M | 40% |
| Other | $7.3M | 7% |
